SOTAC2024-07-012024-09-30 SOTAC2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member SOTAC2024-09-30 SOTAC2024-07-012024-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 000000 SOTAC NOTLISTED INE0O2D01012 Sotac Pharmaceuticals Limited Nonbanking Format SME/ITP 2024-04-01 2025-03-31 2024-10-29 2024-10-24 INR Lakhs Half yearly Single segment Manufacturing of a Wide range of Pharmaceutical Products 15:30:00 16:00:00 2024-10-29 2024-10-29 true Cash Flow Indirect Not applicable 2024-04-01 2024-09-30 Unaudited Standalone 306142000.00 9225000.00 315367000.00 200295000.00 7176000.00 13321000.00 9797000.00 4958000.00 11998000.00 39394000.00 286939000.00 28428000.00 -4000.00 28424000.00 0.00 28424000.00 7610000.00 -350000.00 7260000.00 21164000.00 0.00 0.00 0.00 21164000.00 21164000.00 110500000.00 10 1.92 1.92 0.00 0.00 0.00 [1) The standalone unaudited financial results are prepared in accordance with the Accounting Standards Prescribed urder Section 133 of the Companies Act,2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable. [2) The above standalone unaudited financial resu lts for the Half year ended September 30, 2024 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on October 29,2024, A limited review of the above results has been carried out by the statutory auditors of the company. [3) The figures for the Half year ended 31st March 2024 are the Balancing figures between the au dited figures in respect of full financial year and the audited figures in respect of first Half of the Fin ancial year 2023-24. [4) The figures of the previous period have been re-grouped I rearranged and/ or recasted wherever considered necessary. [5) Company is mainly engaged in manufacturing of of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta- lactam Syrup and external preparations looking into the nature of business company is operating under single segment, hence segment reporting is not applicable to Company. [6) The Status of investor's complaints during the Half year ended on September 30 ,2024 as under:- Complaints pending at the beginning of the period Nill . Complaints received during the period Nill Complaints disposed during the period Nill Complaints resolved at the end of the period Nill OTHER EXPENSES 39394000.00 110500000.00 393325000.00 0.00 503825000.00 0.00 0.00 37635000.00 0.00 0.00 0.00 1576000.00 39211000.00 67320000.00 115824000.00 80319000.00 18384000.00 12979000.00 294826000.00 837862000.00 169593000.00 0.00 237000.00 0.00 454000.00 0.00 170284000.00 155334000.00 1612000.00 0.00 0.00 0.00 327230000.00 0.00 96549000.00 232494000.00 2336000.00 0.00 111838000.00 67415000.00 510632000.00 837862000.00 4958000.00 11998000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 16956000.00 13684000.00 -12371000.00 -48565000.00 48645000.00 8352000.00 -222000.00 9523000.00 26479000.00 54903000.00 0.00 0.00 -6258000.00 1835000.00 0.00 46810000.00 0.00 0.00 46810000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43000.00 5176000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6258000.00 0.00 -40352000.00 0.00 -39227000.00 0.00 0.00 -39227000.00 0.00 0.00 0.00 0.00 6706000.00 0.00 4958000.00 0.00 0.00 -11664000.00 0.00 0.00 -11664000.00 -4081000.00 0.00 -4081000.00 6417000.00 2336000.00